CRISPR 유전체 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 질환 유형별, 치료 유형별, 투여 방법별, 최종사용자별, 표적 유전자 변형별, 지역별, 경쟁별(2020-2030년)

Global Crispr Genomic Cure Market was valued at USD 2.95 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 25.15% through 2030. The global CRISPR genomic cure market is a rapidly evolving sector within the biotechnology and healthcare industries. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized gene editing and holds immense promise for treating various genetic and hereditary diseases.

Key Market Drivers

Increasing Prevalence of Genetic Disorders and Chronic Diseases

The growing incidence of genetic disorders and chronic diseases is a major driver behind the rapid expansion of the Global CRISPR Genomic Cure Market. Genetic disorders and congenital abnormalities affect approximately 2%-5% of all live births, contributing to up to 30% of pediatric hospital admissions and accounting for nearly 50% of childhood mortality in industrialized nations. These figures highlight a critical demand for advanced genomic interventions, positioning CRISPR-based therapies as a transformative solution in pediatric healthcare. As the burden of hereditary and chronic illnesses continues to rise worldwide, there is an increasing demand for innovative, targeted, and long-term solutions to treat these conditions. CRISPR-based gene editing has emerged as a groundbreaking approach, offering precise and potentially curative treatments for diseases with a strong genetic basis. The incidence of genetic disorders and chronic diseases is increasing due to factors such as aging populations, environmental influences, and inherited genetic mutations. Annually,

Key Market Challenges

Ethical and Regulatory Hurdles

Perhaps one of the most significant challenges is the ethical and regulatory landscape surrounding CRISPR technology. The ethical debate over gene editing in humans, particularly germline editing, remains a contentious issue. Regulatory agencies worldwide are grappling with the need to strike a balance between fostering innovation and ensuring safety and ethical considerations.

Key Market Players

• Merck KGaA
• Takara Bio Inc
• Lonza Group AG
• Horizon Discovery Group Ltd
• Genscript Biotech Corp
• Synthego Corp
• Precision BioSciences Inc
• Mammoth Biosciences Inc
• Thermo Fisher Scientific Inc
• Intellia Therapeutics Inc

Report Scope:

In this report, the Global Crispr Genomic Cure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crispr Genomic Cure Market, By Disease Type:

• Genetic Disorders
• Cancer
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disorders
• Blood Disorders
• Metabolic Disorders
• Others

Crispr Genomic Cure Market, By Therapy Type:

• Gene Editing
• Gene Therapy
• Cell Therapy
• Immunotherapy

Crispr Genomic Cure Market, By Delivery Method:

• In vivo
• Ex vivo

Crispr Genomic Cure Market, By End User:

• Hospitals & Clinics
• Research Institutes
• Biotechnology & Pharmaceutical Companies

Crispr Genomic Cure Market, By Targeted Genetic Modification:

• Single Gene Modification
• Multiple Gene Modification
• Genome-wide Modification

Crispr Genomic Cure Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Crispr Genomic Cure Market.

Available Customizations:

Global Crispr Genomic Cure market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Crispr Genomic Cure Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
  • 5.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
  • 5.2.3. By Delivery Method (In vivo, Ex vivo)
  • 5.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
  • 5.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Crispr Genomic Cure Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy Type
  • 6.2.3. By Delivery Method
  • 6.2.4. By End User
  • 6.2.5. By Targeted Genetic Modification
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Crispr Genomic Cure Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy Type
      • 6.3.1.2.3. By Delivery Method
      • 6.3.1.2.4. By End User
      • 6.3.1.2.5. By Targeted Genetic Modification
  • 6.3.2. Canada Crispr Genomic Cure Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy Type
      • 6.3.2.2.3. By Delivery Method
      • 6.3.2.2.4. By End User
      • 6.3.2.2.5. By Targeted Genetic Modification
  • 6.3.3. Mexico Crispr Genomic Cure Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy Type
      • 6.3.3.2.3. By Delivery Method
      • 6.3.3.2.4. By End User
      • 6.3.3.2.5. By Targeted Genetic Modification

7. Europe Crispr Genomic Cure Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy Type
  • 7.2.3. By Delivery Method
  • 7.2.4. By End User
  • 7.2.5. By Targeted Genetic Modification
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Crispr Genomic Cure Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy Type
      • 7.3.1.2.3. By Delivery Method
      • 7.3.1.2.4. By End User
      • 7.3.1.2.5. By Targeted Genetic Modification
  • 7.3.2. United Kingdom Crispr Genomic Cure Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy Type
      • 7.3.2.2.3. By Delivery Method
      • 7.3.2.2.4. By End User
      • 7.3.2.2.5. By Targeted Genetic Modification
  • 7.3.3. Italy Crispr Genomic Cure Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy Type
      • 7.3.3.2.3. By Delivery Method
      • 7.3.3.2.4. By End User
      • 7.3.3.2.5. By Targeted Genetic Modification
  • 7.3.4. France Crispr Genomic Cure Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy Type
      • 7.3.4.2.3. By Delivery Method
      • 7.3.4.2.4. By End User
      • 7.3.4.2.5. By Targeted Genetic Modification
  • 7.3.5. Spain Crispr Genomic Cure Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy Type
      • 7.3.5.2.3. By Delivery Method
      • 7.3.5.2.4. By End User
      • 7.3.5.2.5. By Targeted Genetic Modification

8. Asia-Pacific Crispr Genomic Cure Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy Type
  • 8.2.3. By Delivery Method
  • 8.2.4. By End User
  • 8.2.5. By Targeted Genetic Modification
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Crispr Genomic Cure Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy Type
      • 8.3.1.2.3. By Delivery Method
      • 8.3.1.2.4. By End User
      • 8.3.1.2.5. By Targeted Genetic Modification
  • 8.3.2. India Crispr Genomic Cure Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy Type
      • 8.3.2.2.3. By Delivery Method
      • 8.3.2.2.4. By End User
      • 8.3.2.2.5. By Targeted Genetic Modification
  • 8.3.3. Japan Crispr Genomic Cure Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy Type
      • 8.3.3.2.3. By Delivery Method
      • 8.3.3.2.4. By End User
      • 8.3.3.2.5. By Targeted Genetic Modification
  • 8.3.4. South Korea Crispr Genomic Cure Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy Type
      • 8.3.4.2.3. By Delivery Method
      • 8.3.4.2.4. By End User
      • 8.3.4.2.5. By Targeted Genetic Modification
  • 8.3.5. Australia Crispr Genomic Cure Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy Type
      • 8.3.5.2.3. By Delivery Method
      • 8.3.5.2.4. By End User
      • 8.3.5.2.5. By Targeted Genetic Modification

9. South America Crispr Genomic Cure Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy Type
  • 9.2.3. By Delivery Method
  • 9.2.4. By End User
  • 9.2.5. By Targeted Genetic Modification
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Crispr Genomic Cure Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy Type
      • 9.3.1.2.3. By Delivery Method
      • 9.3.1.2.4. By End User
      • 9.3.1.2.5. By Targeted Genetic Modification
  • 9.3.2. Argentina Crispr Genomic Cure Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy Type
      • 9.3.2.2.3. By Delivery Method
      • 9.3.2.2.4. By End User
      • 9.3.2.2.5. By Targeted Genetic Modification
  • 9.3.3. Colombia Crispr Genomic Cure Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy Type
      • 9.3.3.2.3. By Delivery Method
      • 9.3.3.2.4. By End User
      • 9.3.3.2.5. By Targeted Genetic Modification

10. Middle East and Africa Crispr Genomic Cure Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy Type
  • 10.2.3. By Delivery Method
  • 10.2.4. By End User
  • 10.2.5. By Targeted Genetic Modification
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Crispr Genomic Cure Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy Type
      • 10.3.1.2.3. By Delivery Method
      • 10.3.1.2.4. By End User
      • 10.3.1.2.5. By Targeted Genetic Modification
  • 10.3.2. Saudi Arabia Crispr Genomic Cure Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy Type
      • 10.3.2.2.3. By Delivery Method
      • 10.3.2.2.4. By End User
      • 10.3.2.2.5. By Targeted Genetic Modification
  • 10.3.3. UAE Crispr Genomic Cure Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy Type
      • 10.3.3.2.3. By Delivery Method
      • 10.3.3.2.4. By End User
      • 10.3.3.2.5. By Targeted Genetic Modification

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Crispr Genomic Cure Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Merck KGaA
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Takara Bio Inc
• 14.3. Lonza Group AG
• 14.4. Horizon Discovery Group Ltd
• 14.5. Genscript Biotech Corp
• 14.6. Synthego Corp
• 14.7. Precision BioSciences Inc
• 14.8. Mammoth Biosciences Inc
• 14.9. Thermo Fisher Scientific Inc
• 14.10.Intellia Therapeutics Inc.

15. Strategic Recommendations

16. About Us & Disclaimer